Welcome to our dedicated page for Ceribell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell insider sale reported on Form 4. Senior Vice President, Finance and PAO David Foehr sold 866 shares of Ceribell, Inc. (ticker CBLL) on 08/27/2025 at a weighted average price of $11.71. After the sale he is shown as beneficially owning 20,250 shares reported as direct ownership. The filing was signed by an attorney-in-fact on 08/29/2025. The form discloses the sale price range was $11.71–$11.72 and notes the reporting person will provide per-transaction detail upon request.
CeriBell, Inc. (CBLL) submitted a Form 144 reporting a proposed sale of 866 common shares, with an aggregate market value of $10,142.93. The shares are part of a restricted stock vesting acquired on 08/20/2025 and paid as compensation. The sale is planned through Fidelity Brokerage Services LLC on 08/27/2025 and the securities trade on NASDAQ. The filer certifies no undisclosed material adverse information about the issuer. There were no sales by the filer in the prior three months reported.
Ceribell, Inc. (CBLL) reporting person Joseph S. Manni, Chief Revenue Officer, disclosed a sale of 660 shares of common stock on 08/25/2025 at a reported price of $11.58 per share. After the transaction he beneficially owns 27,761 shares directly. The filing indicates a routine insider sale with remaining meaningful ownership by the officer.
Ceribell, Inc. insider sale disclosed. David Foehr, Senior VP, Finance and PAO and a company officer, sold 484 shares of Ceribell common stock on 08/25/2025 at $11.58 per share. After the sale he beneficially owns 21,116 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025, documenting the transaction and reporting compliance.
Ceribell, Inc. (CBLL) reporting person Raymond Woo, Chief Technology Officer, disclosed an open-market sale of 687 shares of common stock on 08/25/2025 at a price of $11.58 per share. After the transaction he beneficially owned 147,704 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025. No derivative transactions were reported.
Ceribell, Inc. (CBLL) director and President & CEO Jane (Xingjuan) Chao reported a sale of 2,887 shares of common stock on 08/25/2025 at a price of $11.58 per share. After the sale, the filing shows Ms. Chao directly beneficially owns 773,135 shares. The report also discloses an indirect interest of 369,088 shares held by the ACP 2021 Trust, for which she is a co-trustee and from which she disclaims beneficial ownership except to the extent of her pecuniary interest.
The Form 4 was signed by an attorney-in-fact on 08/27/2025. The filing records a routine disposition of shares by an insider who holds substantial direct and indirect positions, and it includes the required explanatory note about the trustee relationship and disclaimer of beneficial ownership.
Ceribell, Inc. (CBLL) insider Scott Blumberg, who is Chief Financial Officer and a director, reported a disposition of 687 shares of common stock on 08/25/2025 at a price of $11.58 per share. After the reported sale, Mr. Blumberg beneficially owned 119,374 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025. The filing lists no derivative transactions or additional explanations.
Joseph M. Taylor, a director of Ceribell, Inc. (CBLL), reported the sale of 7,032 shares of Common Stock on 08/19/2025 at a weighted-average price of $11.76. After the reported disposition, the filing shows the reporting person beneficially owned 59,235 shares. The Form 4 was filed as a single reporting-person filing and was signed by an attorney-in-fact.
CeriBell, Inc. (CBLL) Form 144: This notice reports a proposed sale of 7,032 shares of common stock through Fidelity Brokerage Services on 08/19/2025 with an aggregate market value of $82,690.42 and 36,663,968 shares outstanding. The shares were acquired via restricted stock vesting from the issuer: 414 shares vested on 06/01/2025 and 6,618 shares vested on 06/10/2025, with payment characterized as compensation. The filer states there were no securities sold in the past three months for the account reported and affirms no undisclosed material adverse information is known.